Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity

Proper immunostimulation (“push”) and immune checkpoint blockade (“release”) are both critical for the efficacy of anticancer immunotherapy. We have recently shown that activating Toll-like receptor 9 (TLR9) while specifically blocking signal transducer and activator of transcription 3 (STAT3) in le...

Descripción completa

Detalles Bibliográficos
Autores principales: Kortylewski, Marcin, Kuo, Ya-Huei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006856/
https://www.ncbi.nlm.nih.gov/pubmed/24800162
http://dx.doi.org/10.4161/onci.27441
_version_ 1782314275300179968
author Kortylewski, Marcin
Kuo, Ya-Huei
author_facet Kortylewski, Marcin
Kuo, Ya-Huei
author_sort Kortylewski, Marcin
collection PubMed
description Proper immunostimulation (“push”) and immune checkpoint blockade (“release”) are both critical for the efficacy of anticancer immunotherapy. We have recently shown that activating Toll-like receptor 9 (TLR9) while specifically blocking signal transducer and activator of transcription 3 (STAT3) in leukemic cells enhances their immunogenicity, allowing for CD8(+) T cell-mediated tumor eradication. These findings underscore the therapeutic potential of such a “Push & Release” strategy against hematological malignancies.
format Online
Article
Text
id pubmed-4006856
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-40068562014-05-05 Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity Kortylewski, Marcin Kuo, Ya-Huei Oncoimmunology Author's View Proper immunostimulation (“push”) and immune checkpoint blockade (“release”) are both critical for the efficacy of anticancer immunotherapy. We have recently shown that activating Toll-like receptor 9 (TLR9) while specifically blocking signal transducer and activator of transcription 3 (STAT3) in leukemic cells enhances their immunogenicity, allowing for CD8(+) T cell-mediated tumor eradication. These findings underscore the therapeutic potential of such a “Push & Release” strategy against hematological malignancies. Landes Bioscience 2014-01-03 /pmc/articles/PMC4006856/ /pubmed/24800162 http://dx.doi.org/10.4161/onci.27441 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Kortylewski, Marcin
Kuo, Ya-Huei
Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity
title Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity
title_full Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity
title_fullStr Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity
title_full_unstemmed Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity
title_short Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity
title_sort push and release: tlr9 activation plus stat3 blockade for systemic antitumor immunity
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006856/
https://www.ncbi.nlm.nih.gov/pubmed/24800162
http://dx.doi.org/10.4161/onci.27441
work_keys_str_mv AT kortylewskimarcin pushandreleasetlr9activationplusstat3blockadeforsystemicantitumorimmunity
AT kuoyahuei pushandreleasetlr9activationplusstat3blockadeforsystemicantitumorimmunity

Ejemplares similares